B · Normal
[China Resources Shuanghe: DC7001A capsules have been approved for clinical trials by the U.S. FDA] On October 11, China Resources Shuanghe (600062.SH) announced that the company’s wholly-owned subsidiary Beijing Shuanghe Runchuang Technology received a notice from the U.S. FDA agreeing to conduct clinical trials of DC7001A capsules. The drug is intended to be used to treat systemic lupus erythematosus and has been approved for drug clinical trials by the State Food and Drug Administration.
Comments